Please use this identifier to cite or link to this item: http://hdl.handle.net/11434/809
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCohney, Solomon (Shlomo)-
dc.contributor.otherYates, Christopher-
dc.contributor.otherColman, P. C.-
dc.contributor.otherFourlanos, S.-
dc.date2013-09-
dc.date.accessioned2016-09-28T04:09:17Z-
dc.date.available2016-09-28T04:09:17Z-
dc.date.issued2014-03-
dc.identifier.citationNephrol Dial Transplant. 2014 Mar;29(3):698-705en_US
dc.identifier.issn0931-0509en_US
dc.identifier.issn1460-2385en_US
dc.identifier.urihttp://hdl.handle.net/11434/809-
dc.description.abstractABO incompatible living donor renal transplantation (ABOi) can achieve outcomes comparable to ABO compatible transplantation (ABOc). However, with the exception of blood group A2 kidneys transplanted into recipients with low titer anti-A antibody, regimens generally include antibody removal, intensified immunosuppression and splenectomy or rituximab. We now report a series of 20 successful renal transplants across a range of blood group incompatibilities using conventional immunosuppression alone in recipients with low baseline anti-blood group antibody (ABGAb) titers. Incompatibilities were A1 to O (3), A1 to B (2), A2 to O (2), AB to A (2), AB to B (1), B to A1 (9), B to O (1); titers 1:1 to 1:16 by Ortho. At 36 months, patient and graft survival are 100%. Antibody-mediated rejection (AbMR) occurred in one patient with thrombophilia and low level donor-specific anti-HLA antibody. Four patients experienced cellular rejection (two subclinical), which responded to oral prednisolone. This series demonstrates that selected patients with low titer ABGAb can undergo ABOi with standard immunosuppression alone, suggesting baseline titer as a reliable predictor of AbMR. This reduces morbidity and cost of ABOi for patients with low titer ABGAb and increases the possibility of ABOi from deceased donors.en_US
dc.publisherOxforden_US
dc.subjectDrug Administration Scheduleen_US
dc.subjectHyperglycemiaen_US
dc.subjectImmunosuppressive Agentsen_US
dc.subjectKidney Failure, Chronicen_US
dc.subjectPrednisoloneen_US
dc.subjectRisk Factorsen_US
dc.subjectLiving Donoren_US
dc.subjectAntibody-Mediated Rejectionen_US
dc.subjectAbMRen_US
dc.subjectDepartment of Nephrology, Epworth HealthCare, Richmond, Victoria, Australia.en_US
dc.subjectUroRenal, Vascular Clinical Institute, Epworth HealthCare, Victoria, Australiaen_US
dc.titleDivided dosing reduces prednisolone-induced hyperglycaemia and glycaemic variability: a randomized trial after kidney transplantation.en_US
dc.typeJournal Articleen_US
dc.identifier.doi10.1093/ndt/gft377en_US
dc.identifier.journaltitleNephrology Dialysis Transplantationen_US
dc.description.pubmedurihttps://www.ncbi.nlm.nih.gov/pubmed/24009292en_US
dc.description.affiliatesDepartment of Medicine (Royal Melbourne Hospital), University of Melbourne, Melbourne, VIC, Australiaen_US
dc.description.affiliatesDepartment of Diabetes and Endocrinology, Royal Melbourne Hospital, Melbourne, VIC, Australiaen_US
dc.description.affiliatesDepartment of Nephrology, Royal Melbourne Hospital, Melbourne, VIC, Australiaen_US
dc.description.affiliatesDepartment of Medicine, NorthWest Academic Centre, University of Melbourne, St Albans, VIC, Australiaen_US
dc.type.studyortrialCrossover Designen_US
dc.type.contenttypeTexten_US
Appears in Collections:UroRenal, Vascular

Files in This Item:
File Description SizeFormat 
divided dosing reduces prednisolone.pdf469.29 kBAdobe PDFView/Open


Items in Epworth are protected by copyright, with all rights reserved, unless otherwise indicated.